Informed Consent and Placebo Effects: A Content Analysis of Information Leaflets to Identify What Clinical Trial Participants Are Told about Placebos by Bishop, Felicity L. et al.
 
Informed Consent and Placebo Effects: A Content Analysis of
Information Leaflets to Identify What Clinical Trial Participants Are
Told about Placebos
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Bishop, Felicity L., Alison E. M. Adams, Ted J. Kaptchuk, and
George T. Lewith. 2012. Informed consent and placebo effects: a
content analysis of information leaflets to identify what clinical
trial participants are told about placebos. PLoS ONE 7(6): e39661.
Published Version doi:10.1371/journal.pone.0039661
Accessed February 19, 2015 10:47:34 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10445639
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAInformed Consent and Placebo Effects: A Content
Analysis of Information Leaflets to Identify What Clinical
Trial Participants Are Told about Placebos
Felicity L. Bishop
1*, Alison E. M. Adams
2, Ted J. Kaptchuk
3, George T. Lewith
4
1Psychology, University of Southampton, Southampton, Hampshire, United Kingdom, 2Department of Biology, Northern Arizona University, Flagstaff, Arizona, United
States of America, 3Program in Placebo Studies Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 4Primary
Care and Population Sciences, University of Southampton, Southampton, Hampshire, United Kingdom
Abstract
Background: Placebo groups are used in randomised clinical trials (RCTs) to control for placebo effects, which can be large.
Participants in trials can misunderstand written information particularly regarding technical aspects of trial design such as
randomisation; the adequacy of written information about placebos has not been explored. We aimed to identify what
participants in major RCTs in the UK are told about placebos and their effects.
Methods and Findings: We conducted a content analysis of 45 Participant Information Leaflets (PILs) using quantitative and
qualitative methodologies. PILs were obtained from trials on a major registry of current UK clinical trials (the UKCRN
database). Eligible leaflets were received from 44 non-commercial trials but only 1 commercial trial. The main limitation is
the low response rate (13.5%), but characteristics of included trials were broadly representative of all non-commercial trials
on the database. 84% of PILs were for trials with 50:50 randomisation ratios yet in almost every comparison the target
treatments were prioritized over the placebos. Placebos were referred to significantly less frequently than target treatments
(7 vs. 27 mentions, p,001) and were significantly less likely than target treatments to be described as triggering either
beneficial effects (1 vs. 45, p,001) or adverse effects (4 vs. 39, p,001). 8 PILs (18%) explicitly stated that the placebo
treatment was either undesirable or ineffective.
Conclusions: PILs from recent high quality clinical trials emphasise the benefits and adverse effects of the target treatment,
while largely ignoring the possible effects of the placebo. Thus they provide incomplete and at times inaccurate information
about placebos. Trial participants should be more fully informed about the health changes that they might experience from
a placebo. To do otherwise jeopardises informed consent and is inconsistent with not only the science of placebos but also
the fundamental rationale underpinning placebo controlled trials.
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Introduction
Placebo groups are used in trials to control for placebo effects,
i.e. those changes in a person’s health status that result from the
meaning and hope the person attributes to a procedure or event in
a health care setting [1,2]. These effects can be large, for example
in irritable bowel syndrome [3,4], musculoskeletal pain [5,6], and
depression [7,8], and are underpinned by increasingly well-
understood psychological and neurobiological mechanisms [9–11].
What trial participants are told about placebos is an ethical and a
methodological question. Ethical research conduct requires that
investigators obtain patients’ consent to be randomised to receive
either the target treatment or a placebo. What participants are told
about placebos has implications for the adequacy of this informed
consent process. It also has important implications for the design
and interpretation of randomised clinical trials (RCTs): the
knowledge that one might receive a placebo can influence
patients’ behaviour before, during, and after trials and can even
influence patient-reported outcomes [12].
Before enrolling in trials, knowledge that one might receive
placebo can influence willingness to volunteer: some patients may
be attracted by the chance to receive a placebo [13] while others
are deterred [14]. During trials, patients are typically blinded to
treatment allocation to avoid reporting bias and drop-out.
However, the ambiguity of treatment allocation can be a difficult
experience for participants and some try to discover whether they
are taking placebos or the target treatment [15–18]; if these efforts
at un-blinding are successful they constitute a serious threat to the
validity of any causal inferences, particularly those based on
subjective outcome measures. Indeed, inadequate concealment of
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increase estimates of treatment effects [19,20]. Regardless of the
success of blinding, patients’ beliefs about the likelihood of placebo
allocation are associated with the magnitude of placebo response
[21–24]. Furthermore, merely obtaining informed consent has
been shown to alter the magnitude of placebo effects [25] and
target treatment effects [26]. There is also preliminary evidence
that informing participants that placebos elicit side-effects reduces
patient-reports of side-effects [27], and the same adverse events are
reported in placebo arms as in the corresponding treatment arm of
trials in migraine [28] and depression [29]. After trials, partici-
pants want to know their treatment allocation [30,31] and
participants’ reactions to being told they were receiving a placebo
include surprise, distress, disappointment, and excitement [32–34].
Di Blasi et al suggest that informing patients in advance of possible
beneficial effects of placebos could prevent such distress by
encouraging placebo-responders not to feel tricked if they feel
better [32].
A handful of studies suggest that placebos and their effects are
often poorly understood by members of the general public and
RCT participants [35–38]. This is also true of other technical
aspects of RCTs, such as randomisation and equipoise [39–41].
Information leaflets provide participants with a permanent written
record about a clinical trial and its procedures and thus make an
important contribution to the process of informing participants
about placebos. Previous studies have examined the overall
adequacy of written information about trials [42,43] without
detailing the information given about placebos; hence our research
question: how are placebos described in written information for
trial participants? We conducted a content analysis of participant
information leaflets (PILs) to identify what participants in major
RCTs in the UK are told about placebos and their effects.
Placebo-controlled trials are deemed ethical only when there are
‘‘compelling and scientifically sound methodological reasons’’ that
make placebos necessary ‘‘to determine the efficacy or safety of an
intervention’’ ([44], paragraph 32). We did not know whether this
would be reflected in the ways in which target treatments and
placebos were described in the PILs.
Methods
Data Collection
We searched the major registry of current clinical trials in the
UK (the UK Clinical Research Network database, UKCRN) to
identify trials conducted in clinical populations using a placebo
control. The UKCRN database was chosen as it claims to include
only high-quality trials, summarises each study and provides
contact details. Full eligibility criteria are available from the NIHR
Clinical Research Network [45]. In brief, trials that are
automatically eligible for inclusion are either funded by the NIHR
(or other central government body) or funded by an NIHR partner
(e.g. major charity) which awards funds through open competition
with high quality peer-review and funds research of value to the
NHS and considers the NHS when selecting research to fund.
Industry and investigator-led trials are potentially eligible for
inclusion.
In January 2011, we searched for the terms ‘placebo’ and/or
‘sham’ in the title and/or summary of database records. 334 trials
were identified and contact details were extracted. We sent 182
emails to named contact personnel, inviting them to send in their
PIL(s) for inclusion in our study. Eight individuals were named for
3 or more trials (160 trials total); these 8 individuals were sent just
one email about all of the trials for which they were responsible;
hence, the number of emails sent to contact personnel is less than
the number of trials. In total, 49 PILs out of a possible total of 334
were received, giving a response rate of 13.5%. Four PILs were
excluded (1 was conducted in healthy volunteers, 3 had no placebo
control); the remaining 45 PILs were converted into MS Word
documents to facilitate analysis.
Eligible leaflets were received from 44 non-commercial trials
but only 1 commercial trial. Goodness-of-fit chi-squared tests
confirmed that the characteristics of the responding trials were
similar to those of all non-commercial placebo-controlled trials
registered on the UKCRN database in November 2011 in terms of
funding body (p=0.09), trial type (prevention vs treatment vs
process) (p=0.43) and trial topic (p=0.06), although our sample
contains a greater proportion of phase IV trials (31% vs 9%,
p,0.01).
Data Analysis
We combined qualitative and quantitative techniques of content
analysis [46]. Atlas.ti was used to facilitate the qualitative content
analysis. In phase 1, after repeated reading of the PILs two
researchers independently generated and applied inductive open
codes to summarise how placebos were described, in the context of
target treatments and the whole trial. In phase 2, the researchers
worked collaboratively to develop more abstract categories and
identify the main characteristics attributed to placebos. Premature
conclusions were prevented by frequently reviewing the original
PILs to test out analytic ideas and seek alternative interpretations.
An audit trail of analytic memos, observations, and coding was
maintained.
A spreadsheet was designed in MS Excel to facilitate the
quantitative content analysis. Categorical variables included codes
for characteristics of the target population (condition, age, gender)
and codes for the presence or absence of information about:
possible beneficial and adverse effects of the target and placebo
treatments, un-blinding, and treatment options after the trial.
Numerical variables included the number of times each treatment
was mentioned. Two researchers coded 10 PILs independently
and then discussed discrepancies before independently coding the
remaining 35 PILs. For categorical variables, there was good
overall inter-rater reliability (kappa =0.87); the mean absolute
rate of agreement was 93% (SD =7.9). For numerical variables,
intra-class correlation coefficients ranged from 0.67 to 1.0. All
discrepancies were resolved through discussion. Paired sample t-
tests and McNemar tests for paired proportions were performed to
evaluate quantitative differences between descriptions of target
and placebo treatments. We then integrated these quantitative
findings with our qualitative analysis to describe the key
characteristics of placebos, as represented in the PILs. We have
selected typical quotes to illustrate the results but have not
attributed them to specific trials to maintain investigators’
anonymity in accordance with our ethics approval (SOM-
SEC072.10).
Results
The trials, as described in the PILs
The trials were conducted for a range of conditions (e.g.
diabetes, cancer, stroke) and target populations. All PILs were for
randomised trials and all tested a ‘‘drug’’ as the target treatment.
Three trials were for a drug used during surgery; four were for a
nutritional supplement (probiotics, vitamin D). None of the trials
involved placebo surgery or placebo physical or psychological
therapy. Typical PILs were just over 6 A4 pages long (Mean
=6.44 pages, SD=3.13), included at least one logo (Mean =1.63,
SD=0.53), did not specify the age or gender of their target
Informed Consent and Placebo Effects
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(see Table 1). Twelve of the trials (27%) were still recruiting in
November 2011.
Randomisation ratios and references to placebos and
target treatments
In the majority of PILs (38, 84.4%), participants were told they
had a 50% chance of receiving the placebo treatment; the chance
of receiving the placebo was less than 50% in 2 trials (4.4%) and
greater than 50% in 5 trials (11.1%). When describing randomisa-
tion, most PILs (37, 82%) emphasised both the placebo and the
target treatment, e.g. ‘‘each participant will have a 50% chance of
receiving active [target treatment name] and a 50% chance of
receiving placebo (‘‘dummy’’) tablets.’’ Six (13%) emphasised the
participant’s chance of receiving the target treatment (e.g. ‘‘there is
a 1 in 2 chance that you will receive the active treatment’’).
However, in other ways PILs appeared to place more emphasis on
the target treatment than the placebo. The target treatment was
named in the title of 39 PILs (87%) whereas the placebo was
included in the title of 13 PILs (29%; p,001). Figure 1 shows that,
compared with the target treatment, significantly fewer synonyms
were used to describe the placebo (2.3 vs 3.6; t(44) =25.51,
p,001), the placebo was mentioned significantly fewer times (7 vs
27; t(44) =12.81, p,001) and the placebo was mentioned later in
the main body of the PIL (sub-section 4 vs sub-section 2, t(44)
=210.05, p,001).
Placebo as a Scientific Tool
The dominant function of the placebo control group, as
described in the PILs, was as a scientific tool. Overall, 35 PILs
(78%) explained why a placebo control group was being used in
the trial. Typically, the placebo group was described as a
comparator, included so that investigators could determine the
effects of the target treatment; the placebo was a device that
supported the scientific aim of the trial. This was justified with
reference to clinical uncertainty about the target treatment.
‘‘Sometimes we don’t know which way of treating patients is
best. To find out we need to compare the treatment with a
placebo.’’
While the placebo could be seen as a scientific tool, target
treatments had a different function – to generate effects. This
function of a target treatment was embedded in a trial’s overall
aims, typically stated as to test whether a named target treatment
generates specific hypothesised effects. The stated purpose of the
trial rarely referred to the placebo. Indeed, only 2 PILs mentioned
the placebo in this context.
‘‘The purpose is to find out if [drug name] works in treating
[condition] better than placebo.’’
When PILs provided more detailed descriptions of procedures
associated with the placebo, such as randomisation and double-
blinding, these descriptions contributed to an image of the trial as
a scientific endeavour and the placebo as a scientific tool. For
example, PILs described how participants would be randomly
allocated by chance or by computer (not by a doctor or patient’s
choice) to receive either the target treatment or the placebo
treatment. Randomisation was described as important because it:
allows investigators to compare different treatments, can ensure
groups are comparable at the start of a trial, helps to produce
‘‘high quality scientific research’’, and (in one PIL only) ensures
everyone has an equal chance of getting the target treatment.
Explanations of the need for blinding were also provided in
predominantly scientific terms: according to the PILs, blinding
allows a ‘‘good comparison’’ between groups, reduces ‘‘bias’’,
increases ‘‘accuracy’’, ‘‘reliability’’, and ‘‘fairness’’.
The Placebo Looks like the Genuine Medicine but is Inert
PILs commonly reproduced or adapted this phrase:
‘‘A placebo is a ‘‘dummy treatment’’, which looks like the
genuine medicine but contains no active ingredient.’’
The identical visual appearance of the placebo and target
treatments was further substantiated with details such as the
specific colour of all study tablets. Similarly, the procedures that
participants would be expected to follow were described as
identical for both the placebo and target treatments: all study
treatments were to be taken in the same dosage, in the same mode
of delivery, at the same frequency, at the same time. Some PILs
provided quite detailed justifications for these procedural similar-
ities, for example describing them as necessary to maintain
blinding and thus prevent the doctor or the patient from
influencing the results of the trial.
The target and placebo treatments were explicitly described as
very similar or even identical in appearance, but implicitly the
language used to refer to the placebo and the target treatments
emphasised their differences and suggested that being allocated to
the target treatment might be more desirable for an individual
patient. Target treatments were described as genuine, real, and the
focus of the study. They were given scientific names (e.g.
combinations of letters and numbers, Latin-esque names) and/or
were allocated to a class of drug which often clearly implied a
Table 1. Characteristics of the 45 Trials.
Characteristic Frequency Percentage
Participants’ Gender Female only 7 16
Male only 1 2
Not specified 37 82
Participants’ Age Older adults 4 9
Adults 1 2
Children (,16 years) 3 7
Parents of infants 1 2
Not specified 36 80
External Funding
Source
NIHR 15 33
Charity 22 49
Pharmaceutical
company
71 6
MRC 4 9
Other 4 9
None disclosed 3 7
Trial Type Prevention 5 11
Treatment 30 67
Not specified 9 20
Process 1 2
doi:10.1371/journal.pone.0039661.t001
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Placebo treatments were rarely described in their own right (i.e.
without comparison to the target treatment). Stating that the
placebo looks like the ‘‘genuine medicine’’ implies that the placebo
is not genuine. Consistent with this, other terms used to describe
placebos were often derogatory (e.g. ‘‘dummy’’, ‘‘fake’’) and could
not be said to have a similar status as the names given to the target
treatments. A handful of PILs described the constituents of the
placebo (e.g. ‘‘salt water’’) but most did not and one referred to the
placebo as ‘‘nothing at all’’.
In almost all PILs, the primary characteristic that distinguished
the target treatment from an identical-looking ‘‘dummy’’ placebo
was the potency of the former and the relative or absolute
impotence of the latter. All 45 PILs suggested the real treatment
could have a beneficial effect. In comparison, the placebo
treatment was typically described as inert, inactive, or containing
no active ingredient. A few PILs were explicit about the placebo’s
impotence, claiming that it was incapable of eliciting positive (3
PILs, 7%) negative (1 PIL, 2%) or any (1 PIL, 2%) effects at all. An
additional 3 PILs (7%) informed potential participants that the risk
of receiving placebo was a disadvantage of participating in the
trial. Overall therefore 8 PILs (18%) gave a clear message that the
placebo treatment was undesirable or ineffective.
The Placebo Group Might Experience Health Changes
Some PILs implied that people receiving the placebo might
experience either benefits and/or adverse effects while in the trial.
Thirteen PILs (29%) suggested that patients might experience
benefits from other trial-related treatments or procedures, such as
physiotherapy that all patients would receive and the extra
attention and monitoring for trial participants compared to usual
care. Seventeen PILs (38%) described beneficial effects that
Figure 1. Placebo treatments were referred to less frequently than target treatments.
doi:10.1371/journal.pone.0039661.g001
Figure 2. The effects of placebos and target treatments were described differently.
doi:10.1371/journal.pone.0039661.g002
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specific treatment, for example ‘‘taking part in this study may be
beneficial to you.’’ Similarly, some PILs described possible adverse
effects which were attributed to common treatments (n=22, 49%)
or which were not attributed explicitly to either the placebo or the
target treatment (n=26, 58%).
‘‘You will also be asked questions about any possible side
effects you might be having from the study tablets.’’
In a small minority of PILs, the placebo itself was described as
capable of eliciting effects. One PIL suggested the placebo could
be beneficial (‘‘it may surprise you that the placebo is likely to
significantly help some people with their condition’’) and four PILs
(9%) suggested that the placebo treatment could have adverse
effects (e.g. ‘‘some people will also get side effects when taking the
placebo, the ‘dummy treatment’’’); none provided any rationale or
explanation for how the placebo treatment might produce an
effect. This was very different to how the target treatments were
described: all target treatments were described as potentially
beneficial, 39 (87%) were described as potentially having adverse
effects, and all PILs provided a rationale for the target treatment’s
effects (Figure 2).
Placebos at the End of a Trial
Un-blinding to treatment allocation was mentioned in 14 PILs
(31%): ‘‘We can tell you at the end which treatment group you
were in, if you want to know.’’ In total, 15 PILs described
participants’ options for continuing treatment after the trial.
Twelve of these offered the target treatment to participants who
had received it during the trial, to participants who had received
the placebo during the trial, or to patients in general.
‘‘As the drugs are already licensed in other indications there
is the possibility that the drugs could be available to NHS
patients.’’
The possibility of continuing on the placebo treatment after the
trial was never raised explicitly. However, four PILs mentioned the
possibility of continuing on the ‘‘study treatment’’ or ‘‘study
medication’’ (which, because it had not been previously defined,
could be interpreted as including placebo).
‘‘If your [condition] is showing signs of responding to study
treatment, and you are not experiencing significant side
effects, the treatment cycles may continue.’’
Discussion
We used content analysis to compare descriptions of placebos
and target treatments in a sample of 45 PILs from recent clinical
trials. While the majority of our PILs had a 50:50 randomisation
ratio, in almost every comparison we made the target treatments
were prioritized over the placebo, from the words in the title to the
description of what would happen at the end of the trial. PILs
emphasised the benefits and adverse effects that might be triggered
by the target treatment, while largely ignoring those that might be
triggered by the placebo. This is inconsistent with the basic
rationale for including a placebo control, that the efficacy of the
target treatment in comparison with a placebo is unknown. If
patients in the placebo group might experience health changes
during a trial, then it would seem that an ethical and transparent
information leaflet would acknowledge this and provide an
explanation that draws on known mechanisms of placebo effects.
If it is certain that patients in the placebo group will not experience
any health changes during a trial, then using a placebo group
would seem scientifically unnecessary and ethically questionable.
The main strength of this study is the use of complementary
qualitative and quantitative techniques of content analysis, which
allowed us to compare statistically the number of times placebos
and target treatments were presented in particular ways and to
explore in detail the different ways in which placebos were
described. By using the UKCRN database we ensured that we
only included PILs from high-quality recent RCTs. Unfortunately,
our response rate was low, probably due to a very conservative
recruitment strategy. This is a limitation. We received only one
PIL from a commercial study and all PILs received were for
placebo drugs (rather than, for example, placebo surgery or
therapy). A more aggressive recruitment strategy (repeated
contact, telephone contact) might have helped obtain PILs from
commercial studies. Further work is certainly needed to ascertain
how placebos are described in commercial studies, whether this is
different to non-commercial trials, and how different types of
placebos are described in general. However, our PILs came from a
sample of trials which was broadly representative of all non-
commercial placebo-controlled trials on the UKCRN database.
Furthermore, the pattern of results was a) strong across the PILs
which represented a wide variety of studies and b) consistent with
the UK Clinical Research Collaboration’s information booklet
[47], suggesting our findings might be generally applicable to non-
commercial trials within the UK context. Similar to our results,
the UK Clinical Research Collaboration’s information booklet for
prospective clinical trial participants also describes placebos as
looking like the genuine medicine while clearly implying that it is
clinically inert:
Table 2. How Placebos Could be More Fully Described [3].
Explain that ‘‘the placebo pill is an inactive (i.e., ‘‘inert’’) substance like a sugar pill that contains no medication’’. Then explain four key features of
the placebo effect:
‘‘1) the placebo effect is powerful,
2) the body can automatically respond to taking placebo pills like Pavlov’s dogs who salivated when they heard a bell,
3) a positive attitude helps but is not necessary, and
4) taking the pills faithfully is critical.’’
Note. This description reproduced from a recent open-label trial of placebos [3].
doi:10.1371/journal.pone.0039661.t002
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the treatment being tested. For example, in a drug trial the
placebo looks exactly like the real drug, but in fact it is
inactive. By comparing people’s responses to the placebo
and to the treatment being tested, researchers can tell
whether the treatment is having any real benefit.’’[47].
We have been unable to locate other recent systematic empirical
analyses of the ways in which placebos are described in PILs. Our
findings can help to explain the results of other, related, studies.
The dominant rhetoric of the PILs in this study encouraged
participants to focus on the target treatment and to see the placebo
as an inert scientific tool, a ‘‘dummy’’. This helps to explain why
some RCT participants conceptualise placebos as ineffective [48]
and have been shown to have low levels of knowledge and
understanding about placebos and their effects [35,36]. Only a
small minority of PILs mentioned that people in the placebo group
might also experience health changes and none explained how this
might come about. It is therefore not surprising that participants
who have experienced health changes can be surprised, confused,
and/or disappointed when told that they have been receiving
placebo [33,34]. If randomisation ratios that strongly favour the
target treatment do enhance the placebo response [21] then an
almost exclusive focus on the target treatment in written
information, including a strong scientific rationale for its possible
effects, could have a similar effect by encouraging patients to
attribute any symptom changes to the target treatment thus
potentially increasing treatment response in all study groups. This
could also have important implications for establishing the effect
size of the study treatments.
There is a clear ethical need for greater transparency and
greater respect for persons in the provision of written information
about placebos. One approach would be to continue to provide
detailed scientific explanations concerning the target treatment but
to supplement this with more information about the placebo. This
could include a rationale for why health changes might be
experienced by the placebo group. A recent open-label placebo
trial [3] provides an example of how placebos might be more fully
described (Table 2). An alternative would be to provide
information about the effects and procedures that all participants
in the trial might experience, without distinguishing between those
receiving the target treatment and the placebo. Different trials
might require different approaches as some conditions and
methods, such as illnesses with greater natural fluctuation and
subjective outcomes, are more susceptible to placebo effects than
others [49,50]. Trials in conditions that are known to have strong
placebo responses (e.g. IBS [3,4], musculoskeletal pain [5,6],
depression [7,8]) might emphasise the possible effects and well-
established mechanisms of placebo, while trials in conditions that
are less responsive to placebos might emphasise the processes that
can lead participants in the placebo group to perceive improve-
ment (e.g. interventions that both the placebo and target treatment
group receive).
Future research should explore verbal communication between
trial personnel and trial participants about the placebo treatment.
Different ways of describing placebos to participants, on PILs and
in person, should be developed and tested; ethics committees and
other similar review boards should be involved in such work, given
their potential to guide, sanction, and enforce practices in this
area. In particular, future studies should test the effects of different
information about placebos on recruitment rates, the placebo
effect size, and participants’ experiences of being told their
treatment allocation. Trial participants should be provided with
more complete and accurate written information about placebos
to ensure consent is truly informed.
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